Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL versus PROMETRIUM.
NORETHINDRONE AND ETHINYL ESTRADIOL vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Thickens cervical mucus to inhibit sperm penetration. Alters endometrium to reduce implantation likelihood.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
One tablet (norethindrone 1 mg / ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal, mean ~17 hours). Half-life supports once-daily dosing for contraceptive efficacy.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Norethindrone: ~50% renal (as metabolites), ~50% fecal (biliary). Ethinyl estradiol: ~40% renal, ~60% fecal (primarily as glucuronide conjugates).
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category D/X
Category C
Progestin
Progestin